Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C29H41NO4 |
Molecular Weight | 467.6401 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[H][C@@]12OC3=C4C(C[C@H]5N(CC6CC6)CC[C@@]14[C@@]57CC[C@@]2(OC)[C@]([H])(C7)[C@](C)(O)C(C)(C)C)=CC=C3O
InChI
InChIKey=RMRJXGBAOAMLHD-IHFGGWKQSA-N
InChI=1S/C29H41NO4/c1-25(2,3)26(4,32)20-15-27-10-11-29(20,33-5)24-28(27)12-13-30(16-17-6-7-17)21(27)14-18-8-9-19(31)23(34-24)22(18)28/h8-9,17,20-21,24,31-32H,6-7,10-16H2,1-5H3/t20-,21-,24-,26+,27-,28+,29-/m1/s1
Molecular Formula | C29H41NO4 |
Molecular Weight | 467.6401 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Buprenorphine is an opioid analgesic, used to treat opioid addiction, moderate acute pain, and moderate chronic pain. Buprenorphine is a partial agonist at the mµ-opioid receptor and an antagonist at the kappa-opioid receptor. One unusual property of buprenorphine observed in vitro studies is its very slow rate of dissociation from its receptor. This could account for its longer duration of action than morphine, the unpredictability of its reversal by opioid antagonists, and its low level of manifest physical dependence. The principal action of the therapeutic value of buprenorphine is analgesia and is thought to be due to buprenorphine binding with high affinity to opioid receptors on neurons in the brain and spinal cord. Buprenorphine produces respiratory depression by direct action on brain stem respiratory centers. The respiratory depression involves a reduction in the responsiveness of the brain stem respiratory centers to both increases in carbon dioxide tension and electrical stimulation. Buprenorphine causes a reduction in motility associated with an increase in smooth muscle tone in the antrum of the stomach and duodenum. Digestion of food in the small intestine is delayed and propulsive contractions are decreased. Buprenorphine produces peripheral vasodilation, which may result in orthostatic hypotension or syncope. Manifestations of histamine release and/or peripheral vasodilation may include pruritus, flushing, red eyes, sweating, and/or orthostatic hypotension.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL233 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063 |
1.5 nM [Ki] | ||
Target ID: CHEMBL237 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063 |
2.5 nM [Ki] | ||
Target ID: CHEMBL236 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063 |
6.1 nM [Ki] | ||
Target ID: P41146 Gene ID: 4987.0 Gene Symbol: OPRL1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063 |
77.4 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | BUTRANS Approved UseSUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date1.27785606E12 |
|||
Primary | BUTRANS Approved UseSUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date1.27785606E12 |
|||
Primary | BUTRANS Approved UseSUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date1.27785606E12 |
|||
Primary | BUTRANS Approved UseSUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date1.27785606E12 |
|||
Primary | BUTRANS Approved UseSUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence and should be used as part of a complete treatment plan to include counseling and psychosocial support. Under the Drug Addiction Treatment Act (DATA) codified at 21 U.S.C. 823(g), prescription use of this product in the treatment of opioid dependence is limited to physicians who meet certain qualifying requirements, and who have notified the Secretary of Health and Human Services (HHS) of their intent to prescribe this product for the treatment of opioid dependence and have been assigned a unique identification number that must be included on every prescription. SUBOXONE sublingual film is indicated for maintenance treatment of opioid dependence. Prescription use of this product is limited under the Drug Addiction Treatment Act. (1) Launch Date1.27785606E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.17 ng/mL |
75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered: |
BUPRENORPHINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
0.63 ng × h/mL |
75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered: |
BUPRENORPHINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3 h |
75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered: |
BUPRENORPHINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
4% |
75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered: |
BUPRENORPHINE plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
5.714 ug/kg 1 times / day single, intravenous Studied dose Dose: 5.714 ug/kg, 1 times / day Route: intravenous Route: single Dose: 5.714 ug/kg, 1 times / day Sources: |
healthy, 22 to 35 years n = 5 Health Status: healthy Age Group: 22 to 35 years Sex: M Population Size: 5 Sources: |
Other AEs: Respiratory depression... Other AEs: Respiratory depression Sources: |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Disc. AE: Nausea, Vomiting... AEs leading to discontinuation/dose reduction: Nausea (4.4%) Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53Vomiting (1.6%) Constipation (0.8%) Dizziness (1.4%) Headache (1.1%) Somnolence (1.1%) Fatigue (0.8%) QT interval prolonged (0.5%) Anxiety (0.5%) |
32 mg 1 times / day single, oral Highest studied dose Dose: 32 mg, 1 times / day Route: oral Route: single Dose: 32 mg, 1 times / day Sources: |
healthy, mean age 32.3 years n = 4 Health Status: healthy Age Group: mean age 32.3 years Sex: M Population Size: 4 Sources: |
|
0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 36 patients) Sources: Vomiting (below serious, 24 patients) Constipation (below serious, 9 patients) Dizziness (below serious, 18 patients) Headache (below serious, 15 patients) Somnolence (below serious, 6 patients) Pruritus (below serious, 2 patients) Hyperhidrosis (below serious, 2 patients) Oxygen saturation decreased (below serious, 6 patients) Hot flush (below serious, 2 patients) |
0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Other AEs: Nausea, Vomiting... Other AEs: Nausea (below serious, 47 patients) Sources: Vomiting (below serious, 33 patients) Constipation (below serious, 6 patients) Dizziness (below serious, 26 patients) Headache (below serious, 23 patients) Somnolence (below serious, 6 patients) Pruritus (below serious, 2 patients) Hyperhidrosis (below serious, 1 patient) Oxygen saturation decreased (below serious, 8 patients) Hot flush (below serious, 2 patients) |
0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Other AEs: Angioedema, Nausea... Other AEs: Angioedema (serious, 1 patient) Sources: Nausea (below serious, 68 patients) Vomiting (below serious, 59 patients) Constipation (below serious, 8 patients) Dizziness (below serious, 44 patients) Headache (below serious, 13 patients) Somnolence (below serious, 11 patient) Pruritus (below serious, 11 patient) Hyperhidrosis (below serious, 8 patients) Oxygen saturation decreased (below serious, 7 patients) Dehydration (below serious, 7 patients) Hot flush (below serious, 5 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Respiratory depression | 5.714 ug/kg 1 times / day single, intravenous Studied dose Dose: 5.714 ug/kg, 1 times / day Route: intravenous Route: single Dose: 5.714 ug/kg, 1 times / day Sources: |
healthy, 22 to 35 years n = 5 Health Status: healthy Age Group: 22 to 35 years Sex: M Population Size: 5 Sources: |
|
Anxiety | 0.5% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
QT interval prolonged | 0.5% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Constipation | 0.8% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Fatigue | 0.8% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Headache | 1.1% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Somnolence | 1.1% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Dizziness | 1.4% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Vomiting | 1.6% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Nausea | 4.4% Disc. AE |
480 ug 2 times / day multiple, oral (mean) Recommended Dose: 480 ug, 2 times / day Route: oral Route: multiple Dose: 480 ug, 2 times / day Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
unhealthy, adult n = 2127 Health Status: unhealthy Condition: pain Age Group: adult Sex: M+F Population Size: 2127 Sources: Page: nda/2015/207932Orig1s000MedR.pdf - p.53 |
Headache | below serious, 15 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Dizziness | below serious, 18 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Hot flush | below serious, 2 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Hyperhidrosis | below serious, 2 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Pruritus | below serious, 2 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Vomiting | below serious, 24 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Nausea | below serious, 36 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Oxygen saturation decreased | below serious, 6 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Somnolence | below serious, 6 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Constipation | below serious, 9 patients | 0.125 mg 3 times / day multiple, sublingual Dose: 0.125 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.125 mg, 3 times / day Sources: |
unhealthy n = 82 Health Status: unhealthy Condition: postoperative pain Population Size: 82 Sources: |
Hyperhidrosis | below serious, 1 patient | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Hot flush | below serious, 2 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Pruritus | below serious, 2 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Headache | below serious, 23 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Dizziness | below serious, 26 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Vomiting | below serious, 33 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Nausea | below serious, 47 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Constipation | below serious, 6 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Somnolence | below serious, 6 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Oxygen saturation decreased | below serious, 8 patients | 0.25 mg 3 times / day multiple, sublingual Dose: 0.25 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.25 mg, 3 times / day Sources: |
unhealthy n = 80 Health Status: unhealthy Condition: postoperative pain Population Size: 80 Sources: |
Pruritus | below serious, 11 patient | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Somnolence | below serious, 11 patient | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Headache | below serious, 13 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Dizziness | below serious, 44 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Hot flush | below serious, 5 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Vomiting | below serious, 59 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Nausea | below serious, 68 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Dehydration | below serious, 7 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Oxygen saturation decreased | below serious, 7 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Constipation | below serious, 8 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Hyperhidrosis | below serious, 8 patients | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Angioedema | serious, 1 patient | 0.5 mg 3 times / day multiple, sublingual Dose: 0.5 mg, 3 times / day Route: sublingual Route: multiple Dose: 0.5 mg, 3 times / day Sources: |
unhealthy n = 81 Health Status: unhealthy Condition: postoperative pain Population Size: 81 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
strong [Ki 14.7 uM] | ||||
strong [Ki 21.4 uM] | ||||
weak [Ki 132 uM] | ||||
weak [Ki 133 uM] | ||||
weak [Ki 146 uM] | ||||
weak [Ki >300 uM] | ||||
weak [Ki >300 uM] | ||||
yes [IC50 47 uM] | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. | 2001 Apr 17 |
|
Simultaneous determination of buprenorphine, norbuprenorphine, and buprenorphine-glucuronide in plasma by liquid chromatography-tandem mass spectrometry. | 2001 Apr 25 |
|
[The benefit of combining spinal morphine and intravenous buprenorphine for perioperative pain]. | 2001 Aug |
|
Effect of perinatal buprenorphine exposure on development in the rat. | 2001 Aug |
|
Buprenorphine sublingual tablets: effects on IV heroin self-administration by humans. | 2001 Feb |
|
Hepatitis after intravenous buprenorphine misuse in heroin addicts. | 2001 Feb |
|
Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. | 2001 Feb |
|
Treating opioid dependence. | 2001 Feb 15 |
|
Response variability to analgesics: a role for non-specific activation of endogenous opioids. | 2001 Feb 15 |
|
[The influence of age on hemodynamics and the dose requirements of propofol and buprenorphine in total intravenous anesthesia]. | 2001 Jan |
|
Agonists determine the pattern of G-protein activation in mu-opioid receptor-mediated supraspinal analgesia. | 2001 Jan 15 |
|
[The effect of intravenous patient controlled analgesia on activities of daily life and medical expense after thoracotomy]. | 2001 Jul |
|
Stimulation of guanosine-5'-o-(3-[35S]thio)triphosphate binding in digitonin-permeabilized C6 rat glioma cells: evidence for an organized association of mu-opioid receptors and G protein. | 2001 Jul |
|
Lack of effect of single high doses of buprenorphine on arterial blood gases in the rat. | 2001 Jul |
|
Buprenorphine added to the local anesthetic for brachial plexus block to provide postoperative analgesia in outpatients. | 2001 Jul-Aug |
|
An exploratory study of buprenorphine use in Bangladesh: a note. | 2001 Jun |
|
Epidural analgesia with a combination of bupivacaine and buprenorphine in rats. | 2001 Jun |
|
The use of analgesic drugs by South African veterinarians. | 2001 Mar |
|
Inefficacy of buprrenorphine in rats. | 2001 Mar |
|
Multiple access to sterile syringes for injection drug users: vending machines, needle exchange programs and legal pharmacy sales in Marseille, France. | 2001 Mar |
|
Development and validation of a sensitive analytical method for the simultaneous determination of buprenorphine and norbuprenorphine in human plasma. | 2001 Mar |
|
Perinatal opioids reduce striatal nerve growth factor content in rat striatum. | 2001 Mar 2 |
|
The effects of chronic morphine on behavior reinforced by several opioids or by cocaine in rhesus monkeys. | 2001 May 1 |
|
Hydrolysis of conjugated metabolites of buprenorphine. I. The quantitative enzymatic hydrolysis of buprenorphine-3-beta-D-glucuronide in human urine. | 2001 Oct |
|
Opioid maintenance: the politics matter. | 2001 Oct |
|
Buprenorphine: better late than never. | 2001 Oct 1 |
|
[Treatment of heroin addiction--clinical findings hand-in-hand with evidence]. | 2001 Oct 10 |
|
[Continuous epidural administration of droperidol for the prevention of postoperative nausea]. | 2001 Sep |
|
Limits to buprenorphine dosing: a comparison between quintuple and sextuple the maintenance dose every 5 days. | 2001 Sep 1 |
|
Deaths involving buprenorphine: a compendium of French cases. | 2001 Sep 15 |
|
Effect of epidural analgesia on postoperative paralytic ileus in chronic schizophrenia. | 2001 Sep-Oct |
Sample Use Guides
The initial starting dose is 1 mL buprenorphine hydrochloride injection (0.3 mg buprenorphine) given by deep intramuscular or slow (over at least 2 minutes) intravenous injection at up to 6-hour intervals, as needed.
Repeat once (up to 0.3 mg) if required, 30 to 60 minutes after initial dosage, giving consideration to previous dose pharmacokinetics, and thereafter only as needed. In high-risk patients (e.g., elderly, debilitated, presence of respiratory disease, etc.) and/or in patients where other CNS depressants are present, such as in the immediate postoperative period, the dose should be limited to the minimum required.
Buprenorphine hydrochloride has been used in pediatric patients 2 to 12 years of age at doses between 2 to 6 micrograms/kg of body weight given every 4 to 6 hours. There is insufficient experience to recommend a dose in infants below the age of two years, single doses greater than 6 micrograms/kg of body weight, or the use of a repeat or second dose at 30 to 60 minutes (such as is used in adults).
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24903063
Functional activity of μ receptors in intact cells was determined by measuring receptor-induced membrane potential change, which can be directly read by Molecular Devices Membrane Potential Assay Kit (Blue Dye) using the FlexStation 3® microplate reader. CHO cells transfected with human μ-opioid receptors were seeded in a 96-well plate (30 000 cells per well) 1 day prior to the experiments. For agonist assays, after brief washing, the cells were loaded with 225 μL of HBSS assay buffer (HBSS with 20 mM of HEPES, pH 7.4), containing the blue dye, and incubated at 37°C. After 30 min, 25 μL of the Buprenorphine were automatically dispensed into the wells by the FlexStation and receptor stimulation-mediated membrane potential change is recorded every 3 s for 60 s by reading 550–565 nm fluorescence excited at 530 nm wavelength.
Substance Class |
Chemical
Created
by
admin
on
Edited
Wed Jul 05 22:45:17 UTC 2023
by
admin
on
Wed Jul 05 22:45:17 UTC 2023
|
Record UNII |
40D3SCR4GZ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QN07BC51
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
NDF-RT |
N0000175685
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
WHO-ATC |
N07BC01
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
LIVERTOX |
NBK548871
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
NDF-RT |
N0000175689
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
DEA NO. |
9064
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
NCI_THESAURUS |
C1506
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
WHO-ATC |
N02AE01
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
NCI_THESAURUS |
C67413
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
79093
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
SUBOXONE (AUTHORIZED: OPIOID-RELATED DISEASES)
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
WHO-ATC |
N07BC51
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
WHO-VATC |
QN07BC01
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
WHO-VATC |
QN02AE01
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
||
|
FDA ORPHAN DRUG |
541116
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
644073
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
1670
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
CHEMBL511142
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
257-950-6
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
C61656
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
1819
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | RxNorm | ||
|
D002047
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
M2771
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | Merck Index | ||
|
3403
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
BUPRENORPHINE
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
40D3SCR4GZ
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
434
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
Buprenorphine
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
40D3SCR4GZ
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
52485-79-7
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
SUB05985MIG
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
3216
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
DTXSID2022705
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
100000085263
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY | |||
|
DB00921
Created by
admin on Wed Jul 05 22:45:17 UTC 2023 , Edited by admin on Wed Jul 05 22:45:17 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET->PARTIAL AGONIST |
PARTIAL AGONIST
BINDING
Ki
|
||
|
BINDER->LIGAND |
BINDING
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
||
|
DERIVATIVE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
BINDING
Ki
|
||
|
TARGET -> AGONIST | |||
|
TARGET -> INHIBITOR |
BINDING
Ki
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
receptor binding and pharmacological activity
|
||
|
METABOLITE ACTIVE -> PARENT |
FECAL; URINE
|
||
|
METABOLITE -> PARENT |
receptor binding and pharmacological activity
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||